Bavarian Nordic Secures Significant European Smallpox/Monkeypox Vaccine Order for 2023
- Bavarian Nordic to supply an additional 1.5 million doses of IMVANEX® vaccine to an undisclosed European country
- Deliveries starting in the fourth quarter of 2022, but with the vast majority of doses to be delivered in 2023
COPENHAGEN, Denmark, July 19, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today that a non-disclosed country has ordered an additional 1.5 million doses of IMVANEX®, a non-replicating smallpox vaccine. While deliveries under this contract will start in 2022, the majority of the doses will be delivered during 2023 and as such this order has no impact on the financial guidance for this year.
Paul Chaplin, President and CEO of Bavarian Nordic said: “While governments and health authorities around the world are busy fighting the current monkeypox outbreak we applaud those governments thinking beyond the current situation and building stockpiles to secure future preparedness and we are proud to assist our customers in both efforts.”
With this order, together with previously announced orders from the US and Canada, Bavarian Nordic now has significant orders of smallpox/monkeypox vaccines, providing a robust basis for 2023.
About the smallpox/monkeypox vaccine
MVA-BN or Modified Vaccinia Ankara-Bavarian Nordic (marketed as IMVANEX® in Europe, JYNNEOS® in the U.S. and IMVAMUNE® in Canada) is a non-replicating smallpox vaccine developed in collaboration with the U.S. government to ensure supply of a smallpox vaccine for the entire population, including immunocompromised individuals who are not recommended vaccination with traditional replicating smallpox vaccines. The vaccine was approved by the European Commission in 2013 for immunization against smallpox in adults aged 18 years and older and has subsequently gained regulatory approvals in Canada and the U.S. where the approval has been extended to include the monkeypox indication as the only vaccine having obtained this to-date.
Bavarian Nordic has ongoing supply contracts with USA and Canada and has delivered the vaccine to a number of undisclosed countries globally as part of their national biological preparedness. In recent years, smaller quantities of the vaccine have been supplied in response to sporadic cases of monkeypox. During the ongoing 2022 outbreak of monkeypox, Bavarian Nordic has worked with several governments to fulfil the immediate demand for the vaccine through a number of supply agreements and is working to secure manufacturing of vaccines to fulfil the demand in the medium- to long term.
About Bavarian Nordic
Bavarian Nordic is a fully integrated vaccines company focused on the development, manufacturing and commercialization of life-saving vaccines. We are a global leader in smallpox vaccines and have been a long-term supplier to the U.S. Government of a non-replicating smallpox vaccine, which has been approved by the FDA, also for the protection against monkeypox. The vaccine is also approved for protection against smallpox and monkeypox in Canada, and as a smallpox vaccine in Europe. Our commercial product portfolio furthermore contains market-leading vaccines against rabies and tick-borne encephalitis. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates designed to save and improve lives by unlocking the power of the immune system, including an Ebola vaccine, which is licensed to the Janssen Pharmaceutical Companies of Johnson & Johnson. We are also committed to the development of a next generation COVID-19 vaccine. For more information visit www.bavarian-nordic.com.
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.
Europe: Rolf Sass Sørensen, Vice President Investor Relations, Tel: +45 61 77 47 43
US: Graham Morrell, Paddock Circle Advisors, firstname.lastname@example.org, Tel: +1 781 686 9600
Company Announcement no. 28/ 2022
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Infinera Completes $373.75 Million Convertible Senior Notes Offering and Repurchases Approximately $300 Million of 2024 Convertible Notes8.8.2022 22:23:04 CEST | Press release
SAN JOSE, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Infinera (NASDAQ: INFN) announced today the closing of its previously announced offering of 3.75% convertible senior notes due 2028 (the “2028 Notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). After the exercise in full of the option to purchase additional 2028 Notes, the aggregate principal amount of 2028 Notes issued in the offering was $373.75 million, with the Company receiving net proceeds (after fees and other expenses) of approximately $362.50 million. The Company used approximately $283.62 million of the net proceeds from this offering to repurchase, including the payment of accrued and unpaid interest, approximately $300 million in aggregate principal amount of its 2.125% Convertible Senior Notes due 2024 in privately negotiated transactions concurrently with the offering. The company intends to use the remaining net proc
CrossAmerica Partners LP Reports Second Quarter 2022 Results8.8.2022 22:15:00 CEST | Press release
Allentown, PA, Aug. 08, 2022 (GLOBE NEWSWIRE) -- CrossAmerica Partners LP Reports Second Quarter 2022 Results Reported Second Quarter 2022 Operating Income of $21.1 million and Net Income of $14.0 million compared to Operating Income of $8.2 million and Net Income of $4.8 million for the Second Quarter 2021Generated Second Quarter 2022 Adjusted EBITDA of $41.4 million and Distributable Cash Flow of $32.4 million compared to Second Quarter 2021 Adjusted EBITDA of $29.7 million and Distributable Cash Flow of $25.0 millionReported Second Quarter 2022 Gross Profit for the Wholesale Segment of $55.0 million compared to $44.2 million of Gross Profit for the Second Quarter 2021Distributed 342.8 million wholesale fuel gallons during the Second Quarter 2022 at an average wholesale fuel margin per gallon of 11.8 cents compared to 331.6 million wholesale fuel gallons at an average wholesale fuel margin per gallon of 9.2 cents during the Second Quarter 2021, an increase of 3% in gallons distribute
Galapagos receives transparency notification from FMR LLC8.8.2022 22:01:00 CEST | Press release
Mechelen, Belgium;8 August 2022, 22.01CET;regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from FMR LLC. Pursuant to Belgian transparency legislation1, Galapagos received a transparency notification on 3 August 2022 from FMR LLC, who notified that it holds 3,739,645 of Galapagos’ voting rights, consisting of ordinary shares (3,707,145) and equivalent financial instruments (32,500). FMR LLC controls investment funds FIAM Holdings LLC, Fidelity Management & Research Company LLC, Fidelity Management Trust Company and Strategic Advisers LLC, of which Fidelity Management & Research Company LLC increased its position to 3,300,782 voting rights, consisting of ordinary shares (3,268,282) and equivalent financial instruments (32,500), representing 5.02% of Galapagos' currently outstanding shares. Hence, this controlled undertaking of FMR LLC group individually crossed the 5% threshold. FMR LLC's holding of 3,739,645 Galapagos' voting rights now
Graduate Management Admission Council Appoints Joy Jones as Incoming CEO8.8.2022 18:00:00 CEST | Press release
Jones to succeed Sangeet Chowfla as head of the global association representing leading graduate business schools RESTON, Va., Aug. 08, 2022 (GLOBE NEWSWIRE) -- The Graduate Management Admission Council (GMAC), a global association of leading graduate business schools, today announced the appointment of Joy Jones as the organization’s CEO-Elect. Jones currently serves as GMAC’s chief product officer and general manager of assessments, a role she has held since July 2017. The announcement came after current CEO Sangeet Chowfla announced his intention to step down from the position earlier this year, and an extensive search executed by a global executive recruiting firm. The GMAC board of directors unanimously voted to elect Jones, who will become GMAC’s fourth CEO as of October 1, 2022. “With more than a hundred interested candidates from around the world, the Board conducted extensive interviews and thorough evaluations over the past months and was thrilled to find the best person to l
GeoJunxion (GOJXN.AS) announces the booking of a series of Location Intelligence Service contracts with combined value of well over one Million Euro8.8.2022 18:00:00 CEST | Press release
Capelle aan den IJssel, The Netherlands – 8 August 2022 – GeoJunxion (GOJXN.AS) is pleased to announce the booking of a series of Location Intelligence Service contracts with combined value of well over one Million Euro. The first 40 days of the new Financial Year 2022/23 (1 July 2022 - 30 June 2023) have been particularly busy and exciting for the various teams in GeoJunxion. As result of this, GeoJunxion is pleased to announce the booking of a series of Location Intelligence Services for one of its major global IT customers, with a combined value well over one Million Euro. In response to an increasing demand for hyper local content, GeoJunxion has closed a series of extensions to existing service contracts and successfully completed the negotiations on a large new tailor-made Location Intelligence Service contract. These new contracts will convert into revenue over the next 3 to 6 months and will contribute substantially to the continued growth of the company’s top- and bottom-line.